Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
**Key Takeaways:**
1. **Governance Instability Weighs on Valuation:** A bitter family feud and high-profile executive departures, including the founder’s son, have cast a shadow over EssilorLuxottica’s corporate governance, contributing significantly to its stock price halving since late last year.
2. **Strategic Shift to Medtech & North American Growth:** Despite internal turmoil, CEO Francesco Milleri is pushing forward with an ambitious strategy to integrate medical services and smart glasses, with a critical focus on expanding market share in the lucrative North American market.
3. **Succession & Investor Confidence in Focus:** The uncertain future of CEO Milleri’s reappointment in 2027, contingent on the fractured Del Vecchio family, creates significant leadership uncertainty that investors will closely monitor as a key determinant of future strategic stability and shareholder value.
—
**EssilorLuxottica Navigates Governance Storm Amid Strategic Pivot**
Milan, [Date] – EssilorLuxottica, the Franco-Italian eyewear behemoth, is currently navigating a period of profound internal upheaval and strategic realignment, factors that have not gone unnoticed by the market. Chief Executive Francesco Milleri has recently orchestrated a significant overhaul of the group’s senior management, a move seen by many as an attempt to streamline operations and reinforce his strategic vision in the wake of a bitter public clash with Leonardo Maria Del Vecchio, the scion of the founding family. This internal discord comes at a critical juncture as the company intensifies its strategic push into North America and seeks to integrate its traditional eyewear manufacturing with a burgeoning medtech business.
The market has reacted sharply to the perceived instability. While EssilorLuxottica maintains its position as the world’s largest eyewear company, boasting revenues that almost doubled under Milleri’s tenure to a record €28.5 billion (likely 2022/2023), its share price has notably **halved since reaching a record high last November**. This dramatic decline underscores investor anxiety surrounding corporate governance, leadership succession, and the potential for strategic derailment caused by the ongoing family dispute.
Milleri’s reorganisation aims to integrate the company’s extensive traditional eyewear operations – encompassing iconic brands like Ray-Ban and Oakley, alongside lens manufacturing giant Essilor – with its rapidly expanding medical technology ventures. According to individuals familiar with the restructuring, the streamlining of the senior team is intended to create a more agile structure capable of executing this complex integration. This strategic pivot into higher-margin medtech and smart glasses represents a crucial growth vector, addressing evolving consumer needs and technological advancements in vision care.
The management reshuffle follows several high-profile departures that have intensified market scrutiny. Most notably, Leonardo Maria Del Vecchio abruptly stepped down last month from his roles as chief strategy officer and president of Ray-Ban. His resignation letter cited a “breakdown in relationship” with Milleri and concerns over the company’s transformation, articulating a sentiment of diminished enthusiasm and belonging within the corporate ranks. This public airing of grievances from a prominent family member sent a clear signal of deep-seated internal divisions, directly impacting investor confidence in the company’s unified direction. The head of R&D and marketing, as well as the chief commercial strategy officer, also exited this summer, further exacerbating concerns about leadership stability.
In the aftermath, Del Vecchio’s former responsibilities will not be directly replaced, signifying a consolidation of power and a deliberate move away from the founder’s family direct operational involvement. Instead, new appointments reflect Milleri’s streamlined vision: Chrystel Barranger has been appointed chief growth officer, Davide Schinetti takes an expanded role as chief operating and R&D officer, and Alfonso Cerullo has been promoted to oversee optical retail and medical and surgical activities specifically in North America. This particular focus on North America is strategically vital, as it represents EssilorLuxottica’s largest and arguably most competitive market. Milleri himself spent nearly three months in the US this year, personally overseeing the expansion into medical services and the burgeoning smart glasses segment, underscoring the strategic imperative of this geographical and technological push.
The underlying tension stems from the ongoing, bitter dispute among the heirs of the late founder, Leonardo Del Vecchio, who passed away in June 2022. The family’s holding company, which holds a crucial 32 per cent controlling stake in EssilorLuxottica, remains a battleground for influence. Leonardo Maria’s earlier failure to secure backing for a €12 billion loan to buy out two of his siblings further highlights the intractable nature of the family’s financial entanglements, which have now spilled into corporate governance.
The gravity of the situation was amplified when Leonardo Maria stated at the Ambrosetti business forum that Milleri’s re-appointment as CEO in April 2027 is “not a given,” a decision that crucially requires the backing of the fractured Del Vecchio family. This public challenge to the CEO’s mandate introduces a significant layer of uncertainty regarding future leadership and strategic continuity, a factor that public markets typically penalise with a “governance discount.” The rapid deterioration of the relationship between Milleri and Leonardo Maria, especially given the latter’s previous endorsement of Milleri as his father’s business heir, has only deepened investor concern over the company’s long-term stability.
While EssilorLuxottica has consistently demonstrated strong revenue growth and market leadership under Milleri, the internal strife has undoubtedly weighed on its reputation and, according to sources, staff morale. The departure of Leonardo Maria’s half-brother, Rocco Basilico, last year, further underscores the familial unraveling within the company’s highest echelons. The market’s reaction, specifically the halving of the share price from its peak, reflects a collective fear among investors that these governance issues could hinder strategic execution, depress future earnings, and potentially destabilise one of the consumer discretionary sector’s most formidable players. The company’s future success now hinges not just on its innovative products and market penetration, but equally on its ability to resolve its internal leadership and family disputes.
**Market Impact:**
The current state of affairs at EssilorLuxottica presents a complex landscape for investors. While the company’s strategic focus on North American growth and diversification into medtech and smart glasses offers compelling long-term potential, the severe governance concerns and leadership uncertainty are significant headwinds. The substantial decline in share price reflects a de-rating by the market, which is now pricing in a higher risk premium due to the family dispute and challenges to the CEO’s authority. Investors will be closely watching for clearer signals on the resolution of the family’s control over Delfin (the holding company), the stability of Milleri’s leadership, and tangible progress in the integration of new business segments, particularly the profitability and scalability of its medical services and smart eyewear initiatives. Until these internal conflicts are decisively resolved, the stock is likely to remain volatile, trading at a discount compared to its intrinsic operational strength and market dominance. The ability of the management team to execute its strategic vision effectively, amidst this backdrop of internal dissent, will be paramount for restoring investor confidence and driving future shareholder value.